Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
89bio, Inc.
Age
22–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥22 years
Willing to enter a medication/lifestyle stabilization period during the screening period, which means maintaining those stable medication, eating, and exercise habits for the duration of the study
Subjects should be on stable background Lipid Modifying Therapy (LMT) to manage ASCVD for a minimum of 4 weeks prior to first qualifying TG
You may not be if
Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening
Type 1 diabetes mellitus
A history of symptomatic gallstone disease, gallstone pancreatitis (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease
Acute pancreatitis within 6 months prior to Screening
Subjects with chronic pancreatitis
Known or suspected familial chylomicronemia syndrome (FCS) (Type 1 hyperlipoproteinemia)
Clareo Health | To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
